Pet Drug Reports

Drugs by active ingredient › Benazepril hydrochloride + Spironolactone

Drug · combination of 2 active ingredients

Benazepril hydrochloride + Spironolactone: adverse event reports

All products with this ingredient combination · 1 FDA-approved application in the Green Book

75reports naming this combination, 2021–20260% of all reports · about 15 a year
11reports, 12 months to March 202619 in the 12 months before
19.2%classed serious, as reportedof 52 reports stating it
6.7%record death or euthanasia, as reported5 reports
69.3%of reports concern dogs0% of all dog reports

75 adverse event reports in FDA's database list a drug whose active ingredients are recorded as the combination benazepril hydrochloride and spironolactone. The earliest was received in March 2021, the latest in March 2026. The Green Book lists 1 FDA-approved application with exactly this combination.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient combination across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 11 reports named it, down 42% from 19 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 15 reports a year and 0% of all 1,357,245 reports (0% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

Reporters most often listed vomiting (14.7%), tablets, Abnormal (10.7%) and diarrhoea (9.3%). A report can list several signs, so shares add to more than 100%; 92 different terms appear across these reports. Vomiting appears in 14.7% of these reports, about the same share as in the pooled reports for every drug containing benazepril hydrochloride (17%).

69.3% of reports concern dogs. Not every report describes illness: 32% as product or packaging defects. Of reports that state seriousness, 19.2% were classed as serious, and 6.7% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog51 · peak 11
Apr 2021: 3Jun 2021: 1Jul 2021: 4Aug 2021: 3Sep 2021: 2Oct 2021: 1May 2022: 2Jun 2022: 2Nov 2022: 1Jun 2023: 11Sep 2023: 1Nov 2023: 1May 2024: 3Jun 2024: 4Aug 2024: 2Sep 2024: 1Nov 2024: 1Jan 2025: 2May 2025: 1Oct 2025: 2Nov 2025: 1Dec 2025: 1Mar 2026: 12022202320242025
Cat0 · peak 1
2022202320242025
Horse0 · peak 1
2022202320242025
Other23 · peak 2
Nov 2021: 1Dec 2021: 1May 2022: 1Sep 2022: 1Nov 2022: 2Dec 2022: 1Apr 2023: 1Jun 2023: 2Nov 2023: 1Jan 2024: 1Aug 2024: 1Oct 2024: 1Dec 2024: 1Jan 2025: 1Feb 2025: 1Mar 2025: 1Jun 2025: 1Aug 2025: 2Oct 2025: 1Nov 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

09172021: 1720212022: 1020222023: 1720232024: 1520242025: 1520252026: 12026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of benazepril hydrochloride + spironolactone reports listing the termall drugs containing benazepril hydrochlorideall dog reports

  1. Vomiting14.7%11
  2. Tablets, Abnormal[a product quality report, not a sign in an animal]10.7%8
  3. Diarrhoea[diarrhea]9.3%7
  4. Lack of efficacy - NOS[the product did not have the expected effect]9.3%7
  5. Product defect, product difficult to use/handle[a product quality report, not a sign in an animal]8%6
  6. Closure, Abnormal[a product quality report, not a sign in an animal]6.7%5
  7. Anorexia[not eating]5.3%4
  8. Appearance, Abnormal[a product quality report, not a sign in an animal]5.3%4
  9. Ataxia[unsteady, uncoordinated movement]5.3%4
  10. Difficulty of Use[a product quality report, not a sign in an animal]5.3%4
  11. Elevated creatinine[a kidney value above the normal range]5.3%4
  12. Lethargy[unusually tired or inactive]5.3%4
  13. Bloody diarrhoea[diarrhea with blood]4%3
  14. Caps, Abnormal[a product quality report, not a sign in an animal]4%3
  15. Collapse NOS[NOS: not otherwise specified]4%3
  16. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]4%3
  17. Emesis[vomiting]4%3
  18. Hypercalcaemia[high blood calcium]4%3
  19. Hyperphosphataemia[high blood phosphate]4%3
  20. Death by euthanasia[the animal was euthanized]2.7%2
  21. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]2.7%2
  22. Elevated serum alkaline phosphatase (ALP)[a liver and bone enzyme above the normal range]2.7%2
  23. Hyperkalaemia[high blood potassium]2.7%2
  24. Hypotension[low blood pressure]2.7%2

Top 30 of 92 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal33.3%25
Recovered with Sequela0%0
Ongoing21.3%16
Died4%3
Euthanized2.7%2
Outcome Unknown8%6

What kind of report it was

Safety issue58.7%44
Lack of expected effectiveness6.7%5
Both safety and lack of expected effectiveness2.7%2
Manufacturing or product defect32%24
Other0%0

Coloured bar: reports naming benazepril hydrochloride + spironolactone. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog69.3%52

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year0%0
1 to 3 years13.3%10
4 to 7 years1.3%1
8 to 11 years21.3%16
12 years and over30.7%23
Age not given33.3%25

Weight of the animal

Under 5 kg (11 lb)14.7%11
5 to 9.9 kg (11–22 lb)32%24
10 to 24.9 kg (22–55 lb)17.3%13
25 to 44.9 kg (55–99 lb)1.3%1
45 kg and over (99 lb+)0%0
Weight not given34.7%26

Route of administration stated in reports: oral (51).

In context

MeasureBenazepril hydrochloride + SpironolactoneAll drugs containing benazepril hydrochlorideAll dog reportsAll reports
Reports75182985,6751,357,245
Share of that pool's reports naming this drug—41.2%0%0%
Classed serious, of reports stating it19.2%41.5%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports66.71545563.8
Filed as lack of expected effectiveness (wholly or partly)9.3%——23%
Top term, share of reportsVomiting 14.7%17%19.7%—

The benazepril hydrochloride pool is every report naming benazepril hydrochloride alone or in any combination; this combination accounts for 41.2% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Spironolactone20048
Benazepril hydrochloride1075

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products containing this combination (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Only one approved application matches this ingredient set. FDA's records still do not say which product a report concerned: the same ingredients are also dispensed as compounded, foreign-labelled and unapproved products, and the ingredient field is completed by whoever submitted the report.

Trade nameActive ingredientsSponsorApproved forApplication
CardalisBenazepril hydrochloride, SpironolactoneCeva Sante AnimaleDogsNADA 141-538

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about benazepril hydrochloride + spironolactone reports

How many adverse event reports has FDA received for the combination benazepril hydrochloride and spironolactone?

75 reports record a drug with the combination benazepril hydrochloride and spironolactone as its active ingredients in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 11 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 1 approved application with this combination; the reference list on this page names them without any counts.

What signs are reported most often?

vomiting (14.7%), tablets, Abnormal (10.7%), diarrhoea (9.3%), lack of efficacy - NOS (9.3%) and product defect, product difficult to use/handle (8%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (69.3%). Among single-breed animals the most frequent labels are Beagle, Chihuahua, Shetland Sheepdog and Shih Tzu; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

11 reports in the 12 months to March 2026, down 42% from 19 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that benazepril hydrochloride + spironolactone harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of benazepril hydrochloride + spironolactone?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.